Pfizer’s Array buyout ranks as 2019’s second largest, but the price sits in a lonely space in the deal universe.
What was up is now down as smaller biotech stocks deal with clinical trial failure and acquisitions.
The Swiss group picks up Spark Therapeutics for $4.8bn, marking the biggest gene therapy buyout since Novartis’s $8.7bn move on Avexis.
In the race to develop a haemophilia B gene therapy Uniqure now has the upper hand.
Bluebird Bio has pushed forward the conversation on how to make million-dollar treatments affordable for insurers, but biopharma and payers are ominously quiet about…
Digging into the sales forecasts for gene therapies shows just how low their penetration is expected to be. Could biopharma come to regret its high-price, low-volume…
The private UK group could steal the thunder of rivals like Spark, Uniqure and Biomarin.
Padua gambit seems to have worked as new gene therapy looks the equal of Pfizer/Spark Therapeutics.
Novartis's $4m price target for AVXS-101 fuels concerns that too many new gene therapies could overburden payers without a hard look at how they are financed.